Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Develops New Heterogeneous Type II Collagen Vaccine

This article was originally published in PharmAsia News

Executive Summary

Chinese People's Liberation Army 307 Hospital immunology laboratory and National Center of Biomedical Analysis' immunological analysis laboratory have developed the world's first heterogeneous type II collagen therapeutic gene vaccine. This is a breakthrough in the country's rheumatoid arthritis biotherapy field, signifying China's therapeutic gene vaccine research has joined the top ranks in the field. Patents have been filed in the U.S., U.K., France, Germany, Japan and China and are in the public appraisal stage. Recently, the vaccine was granted research funds from the national major new drug innovation program and included as an innovative drug with self-developed intellectual property rights. (Click here for more - Chinese language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC070781

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel